MDSpire - Summary
FDA & Government News

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Share

Orforglipron (Foundayo), a once-daily oral GLP-1 receptor agonist developed by Eli Lilly and Company, has been approved by the FDA for chronic weight management in adults with obesity or overweight-related medical conditions. Demonstrating significant weight loss in the ATTAIN clinical trial program, participants lost an average of 27.3 pounds with the highest dose compared to placebo. The drug also showed reductions in cardiometabolic risk markers. Safety warnings include potential thyroid tumors, limiting its use among certain populations. It will be available through various channels starting April 6, 2026, with pricing options for different patient groups.

Original Source(s)

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

  • by Kathryn Wighton

  • April 1, 2026

Related Content

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min
Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens

Your Biological Age? It's in the Blood

Multi-marker model may refine risk prediction and preventive testing

  • April 1, 2026

  • 2 min